BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory BoardNewsfile Corp • 12/04/24
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from NasdaqGlobeNewsWire • 06/24/24
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian CancerGlobeNewsWire • 05/20/24
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/09/24
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung CancerGlobeNewsWire • 04/04/24
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/25/24
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/05/24
Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?Zacks Investment Research • 01/30/24
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 01/29/24
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 01/25/24
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer PatientsGlobeNewsWire • 12/08/23
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast CancerGlobeNewsWire • 11/28/23
eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual MeetingGlobeNewsWire • 11/15/23
eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/13/23
eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare ConferenceGlobeNewsWire • 11/06/23
eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid LeukemiaGlobeNewsWire • 10/24/23